Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Pancreatic and Hepatic Fat in T2DM
NCT05939921Completed
- Sponsor
- Diabetes Foundation
- Start
- May 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of metformin in type 2 diabetes mellitus (T2DM), sponsored by Diabetes Foundation. Primary endpoints: Pancreatic fat content at 4 months and Hepatic fat content at 4 months. Started May 2022; status: completed.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05939921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939921.